Cerus’ Post

Q124 revenues of $6.71 billion, flat both QoQ and YoY. Q224 revenue $6.5 billion, in line with peers. No full year 2024 guidance. WFE has more downside risk than upside potential in 2024.

If you missed the Quarterly Perspectives Q4 2023 webinar from FORVIS, don't worry! Get an overview of standard setter activity for the last quarter of 2023 in this article.

If you missed the Quarterly Perspectives Q4 2023 webinar from FORVIS, don't worry! Get an overview of standard setter activity for the last quarter of 2023 in this article.

Our Q3 results (9 Months) - Revenues At Rs 869 Cr In 9M FY’24, Up 30% YoY; Profit After Tax At Rs 146 Cr, Up 51% YoY

In our latest report, the global edition of our M&A Fee Guide 2023-2024, advisors share what their most common sell-side success fee structure is. Slide to see the results. Read the report here:  fir.mx/FEES24 

Now that we've passed Q1, let's take a quick look back at the #2024predictions for #Australianbusinesses and see how we're faring so far. How's your business holding up? Do you think these forecasts will be fully realised this year? Let us know your thoughts in the comment section! #StellarBusinessConsulting

DIH Holding US, Inc. announced its First Quarter Financial Results for Fiscal 2025, reporting a revenue of $16.2 million for the quarter ended June 30, 2024, representing growth of 24% over the prior year period. The company saw a device revenue of $12.3 million and service revenue of $3.5 million, reflecting growth rates of 18% and 49% respectively and revenue growth in both EMEA and the Americas of 54%. The company reported a Gross Margin of 53.5%, representing a 12 percentage point improvement and a Net loss of $0.6 million, representing improvement of $2.3 million. DIH reiterates its expected full year 2025 revenue range of $74 million to $77 million, representing growth of approximately 15% to 20% over the full year 2024. For more information, view the official press release here. https://lnkd.in/eygyu_vj

Often it can be challenging to understand the #financial #jargon in #earnings #reports. After a conversation with several team members, I realized the importance of explaining these concepts more clearly. Therefore, I want to dedicate this post to #explaining Hologic, Inc. . results for this quarter in a straightforward way, using key numbers and financial terms but also explaining what they mean. Simple Summary of the #Quarter's #Results: Hologic, Inc. . had a #good #quarter, and here are the key points: - #Total #Revenue: Hologic, Inc. . earned a total of $1,011.4 million. This includes all the money the company received from selling #products and #services. This amount is 2.7% higher than what we earned in the same period last year, meaning our #sales have #increased. - #Earnings per Share (#EPS): EPS stands for "earnings per share" and is a way to show how much money the company made for each piece of the company, called a #share. This quarter, Hologic, Inc. made $0.82 for each share. This number is based on #GAAP (Generally Accepted Accounting Principles), which are the rules companies follow when they report their finances. However, sometimes there are special, one-time costs or events that aren't part of the regular business. If we take those out, we get a #Non-GAAP EPS of $1.06. This gives a clearer picture of how the company is doing day-to-day without the unusual events. - #Revenue #Growth: Total revenue increased by 2.7%, indicating #growth in our sales. If we exclude revenue related to COVID-19 products, the growth was 5.8%. This is important because it shows we are #selling more of our other products, not just those related to the pandemic. Performance in Different Areas: - #Diagnostics: In this area, which focuses on tests to detect diseases, we saw a slight increase of 0.3% in revenue. However, within this, molecular diagnostics (which are more specific tests) grew by 2.8%. - #Breast Health: Here, our sales increased by 6.9%, driven by higher demand for imaging equipment for diagnosing breast diseases. - #Surgical Gynecology:This area grew by 5.9%, with products like MyoSure, used in surgeries to treat uterine issues, being particularly popular. Other aspects: - #Share Buyback: Hologic repurchased 1.4 million of its own shares for $100 million. Buying back shares can be a sign that the company is #confident in its #future. - #Acquisition of Endomag:This new #acquisition specializes in technologies for breast surgeries, #expanding our range of products and services. In summary, Hologic, Inc. . had a solid quarter and continues to grow in several key areas. These results show that we are well-positioned to keep improving and #helping #more #people with our health #products. #Congratulations to everyone who is a part of this company and contributes their effort to achieving these strong results. It's a true team effort that keeps us moving forward!

It is always a pleasure to participate in DN Journal's annual state of the industry edition, which I have been asked by Ron Jackson to do since its inception. Here are my thoughts with Hilco Digital Assets and those of so many other successful domain name asset players https://lnkd.in/eS37tEqE #domainnames #domains #digitalassets